Studying the antidepressant effects of intravenous ketamine in patients with major depressive disorder

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12615000566538

Enrollment

Registered

2015-06-02

Start date

2015-06-04

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This randomised controlled trial aims to study the add-on effects of intravenous ketamine to standard oral antidepressant treatment. We hypothesise that this combination may bring about more rapid antidepressant effects compared with oral antidepressant treatment alone.

Interventions

Intravenous Ketamine 0.5mg/kg infusion once per week for 2 weeks

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

21 Years to 65 Years

Healthy volunteers

Inclusion criteria

- Major depressive episode according to DSM-IV-TR Disorders - Montgomery-Asberg Depression Rating Scale score of at least 20 - On stable doses of oral antidepressant medication - Ability to provide informed consent

Exclusion criteria

- Any unstable medical condition or clinically relevant abnormality that is likely to compromise study conduct, evaluation or safety - Schizophrenia and other psychotic disorders, bipolar disorder, obsessive-compulsive disorder, eating disorder, substance-related disorders - Drug allergy to ketamine or scopolamine - Use of adjunct medications for depression and TCAs - Pregnant or breast-feeding women - Inability to follow procedures in the study protocol for any reason

Outcome results